Blood · 2011 · 114 citations · 24 references
MedicineHematologyPharmacotherapyHematopathologyHemostasisAnticoagulant TherapyAnticoagulation TherapyAntithrombotic TherapyPlatelet DisordersPlatelet FunctionThrombosisHeparin AnticoagulationHeparin-induced BleedingHeparin-induced ComplicationsHeparin-mediated AnticoagulationHeparin-protein InteractionsLow-molecular-weight Heparin TherapyMedication-induced ThrombocytopeniaThrombocytopenia Morphology
Heparin is a widely used anticoagulant. Because of its negative charge, it forms complexes with positively charged platelet factor 4 (PF4). This can induce anti-PF4/heparin IgG Abs. Resulting immune complexes activate platelets, leading to the prothrombotic adverse drug reaction heparin-induced thrombocytopenia (HIT). HIT requires treatment with alternative anticoagulants. Approved for HIT are 2 direct thrombin inhibitors (DTI; lepirudin, argatroban) and danaparoid. They are niche products with limitations. We assessed the effects of the DTI dabigatran, the direct factor Xa-inhibitor rivaroxaban, and of 2-O, 3-O desulfated heparin (ODSH; a partially desulfated heparin with minimal anticoagulant effects) on PF4/heparin complexes and the interaction of anti-PF4/heparin Abs with platelets. Neither dabigatran nor rivaroxaban had any effect on the interaction of PF4 or anti-PF4/heparin Abs with platelets. In contrast, ODSH inhibited PF4 binding to gel-filtered platelets, displaced PF4 from a PF4-transfected cell line, displaced PF4/heparin complexes from platelet surfaces, and inhibited anti-PF4/heparin Ab binding to PF4/heparin complexes and subsequent platelet activation. Dabigatran and rivaroxaban seem to be options for alternative anticoagulation in patients with a history of HIT. ODSH prevents formation of immunogenic PF4/heparin complexes, and, when given together with heparin, may have the potential to reduce the risk for HIT during treatment with heparin.
24
Laura Lasagni, Michela Francalanci, Francesco Annunziato et al. · The Journal of Experimental Medicine · 2003 · 747 citations · Full text
Medicine, Cancer Biology, Oncology +14
Dagmar Kubitza, Michael Becka, Georg Wensing et al. · European Journal of Clinical Pharmacology · 2005 · 648 citations
Gian Paolo Visentin, S E Ford, James G. Scott et al. · Journal of Clinical Investigation · 1994 · 555 citations · Full text
Medicine, Hematology, Immunology +17